Literature DB >> 17729062

How can we assess outcomes of clinical trials: the MCID approach.

Barry Make1.   

Abstract

Interpreting changes in outcomes of clinical trials in chronic obstructive pulmonary disease should be viewed from a broader perspective than only the statistical significance of the findings. The minimal clinical difference in outcome measures provides a conceptual framework to assist in clinical trial interpretation and a methodology to assess the clinical relevance of study results. Use of distribution-based techniques, comparison with other external measures, and opinions from experts, clinicians and patients can assist in minimal clinically important difference development. Although the minimal clinically important difference has been suggested for a wide range of outcomes of importance in chronic obstructive pulmonary disease, many have not been subjected to rigorous analysis. For newer tools such as activity monitors and questionnaires and measures not widely employed such as laboratory-based exercise tests, minimal clinically important differences remain to be determined.

Entities:  

Mesh:

Year:  2007        PMID: 17729062     DOI: 10.1080/15412550701471231

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  14 in total

1.  Obesity and Functioning Among Individuals with Chronic Obstructive Pulmonary Disease (COPD).

Authors:  Patricia Katz; Carlos Iribarren; Gabriela Sanchez; Paul D Blanc
Journal:  COPD       Date:  2015-12-18       Impact factor: 2.409

2.  Young Mania Rating Scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohort.

Authors:  Michael Lukasiewicz; Stephanie Gerard; Adeline Besnard; Bruno Falissard; Elena Perrin; Helene Sapin; Mauricio Tohen; Catherine Reed; Jean-Michel Azorin
Journal:  Int J Methods Psychiatr Res       Date:  2013-03-21       Impact factor: 4.035

3.  The impact of disability on depression among individuals with COPD.

Authors:  Patricia P Katz; Laura J Julian; Theodore A Omachi; Steven E Gregorich; Mark D Eisner; Edward H Yelin; Paul D Blanc
Journal:  Chest       Date:  2009-11-20       Impact factor: 9.410

4.  Onset of depressive symptoms among adults with asthma: results from a longitudinal observational cohort.

Authors:  Patricia P Katz; Anne Morris; Laura Julian; Ted Omachi; Edward H Yelin; Mark D Eisner; Paul D Blanc
Journal:  Prim Care Respir J       Date:  2010-09

5.  Long-term antifungal treatment improves health status in patients with chronic pulmonary aspergillosis: a longitudinal analysis.

Authors:  Khaled Al-Shair; Graham T Atherton; Christine Harris; Libuse Ratcliffe; Philippa J Newton; David W Denning
Journal:  Clin Infect Dis       Date:  2013-06-20       Impact factor: 9.079

6.  Responsiveness of Various Exercise-Testing Protocols to Therapeutic Interventions in COPD.

Authors:  Benoit Borel; Steeve Provencher; Didier Saey; François Maltais
Journal:  Pulm Med       Date:  2013-01-28

7.  Is it possible to estimate the minimal clinically important treatment effect needed to change practice in preterm birth prevention? Results of an obstetrician survey used to support the design of a trial.

Authors:  Sue Ross; Jill Milne; Shannon Dwinnell; Selphee Tang; Stephen Wood
Journal:  BMC Med Res Methodol       Date:  2012-03-19       Impact factor: 4.615

Review 8.  Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review.

Authors:  David B Fogel
Journal:  Contemp Clin Trials Commun       Date:  2018-08-07

9.  Inflammatory and repair serum biomarker pattern: association to clinical outcomes in COPD.

Authors:  Victor Pinto-Plata; Ciro Casanova; Hana Müllerova; Juan P de Torres; Henneth Corado; Nerea Varo; Elizabeth Cordoba; Salah Zeineldine; Hildegarde Paz; Rebeca Baz; Miguel Divo; Felipe Cortopassi; Bartolome R Celli
Journal:  Respir Res       Date:  2012-08-20

10.  Why clinical trial outcomes fail to translate into benefits for patients.

Authors:  Carl Heneghan; Ben Goldacre; Kamal R Mahtani
Journal:  Trials       Date:  2017-03-14       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.